Please login to the form below
UK businesses leaning towards second Brexit vote
Poll comes just ahead of May’s ‘plan B’ Brexit announcement
AZ’s Sean Bohen to exit after business overhaul; report
Recent departures raises concern among analysts
GSK upbeat on its return to oncology market
Zejula signals comeback after four year hiatus
Nektar confirms BMS deal for NKTR-214 is on track
Shares in Nektar rose 10% in the wake of the presentation at JPM healthcare conference
Lilly adds to pharma M&A run with $8bn Loxo buy-out
Lilly claims company ahead of more dominant oncology players
Sanofi and Regeneron re-jig immuno-oncology deal
Partners refocus around two promising bispecific candidates
Drug pricing is pharma’s top concern in 2019
More than half of industry respondents say pricing will have the greatest negative impact this year
After December slump, what’s in store for biotech in 2019?
Analysts say 2019 could be a "big year for proceeds if not for deal count"
Blow for J&J as court refuses to overturn talc verdict
Reuters and company at loggerheads over veracity of claims
Health coverage across state lines
Despite a total lack of legislative wins, the new administration has made its presence felt at home and abroad
-
Standing out in a crowdCelltrion Healthcare’s Ho-Ung Kim on pricing, market access and regulatory challenges for successfully developing biosimilars
-
The diseased organisationLike humans, organisations can be afflicted by genetic disorders that hinder performance and threaten survival but these can be understood and cured
-
Novartis buys CellforCure to bolster cell, gene therapyMove would make existing partner an in-house capability
-
First-line ovarian approval cements AZ’s Lynparza leadAlso new data on recently approved kidney disease drug
-
Ex-Pharmacyclics CEO invests $25m in SummitAfter Duchenne drug failure, UK biotech looks to new anti-infective
-
Merck exec steps down, two takes his placeHead of global human health Adam Schechter will transition to CEO advisor
-
Circassia seeks shift to AIM after failing LSE criteriaMove comes after the drug developer suffered a string of immunotherapy defeats
-
Axovant drops last ‘legacy’ drug to focus on gene therapies Decision comes after nelotanserin failed to meet efficacy target
-
Takeda secures investor backing for £46bn Shire takeoverThe deal is expected to close early next year
-
New hires at Nanoform, Leo Pharma and CalliditasThe latest movers in pharma and biotech
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMOLatest movers in pharma and biotech
-
New hires at Mundipharma, Sinclair Pharma and Relay TherapeuticsLatest movers in pharma
-
Ipsen hires general manager, Laura Hamill joins Gilead and Orchard expands leadership teamThe latest industry movers
-
BMS appoints new commercial leader, Davies joins Eisai and moreThe latest industry movers
Latest sales appointments
Featured jobs
-
Senior Medical Writer
-
Salary TBC
-
Account Director
-
Competitive Salary Offered
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Account Manager / Account Director
-
Competative
-
Medical Writer
-
Salary TBC
-
Senior Account Manager
-
Competitive Salary Offered
-
Associate Director
-
£75, 000-90, 000
-
Account Director, Medical Education
-
Salary TBC
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
- Senior Account Director development role to Business Director, H...
-
Excellent package
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Business Director
-
Competitive Salary Offered
- Global Business Development Director – Health Education
-
excellent commission
Subscribe to our email news alerts
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
- FDA expecting boom in cell and gene therapies
- Moving annual total (MAT)
- AZ’s Sean Bohen to exit after business overhaul; report
- FDA moves into crisis mode as shutdown drags on
- Lucid Group prepare for a transformative year with the appointment of a new Director of Corporate Development
PMHub
Complete HealthVizion
Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...
Latest intelligence
- NHS regional footprints
- What to expect from 2019...
- Not another weight-loss ad
- Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
- China’s clinical trial shake-up
- As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Quick links
Infographics
